Crohn's DiseasePhase 3DIVERSITY LTENCT02914600
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
A Phase 3 study testing Filgotinib in people with Crohn's Disease, run by Lakefront Biotherapeutics NV at 486 sites in 40 countries.
Trial summary
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Crohn's Disease
- What is being tested?
- Filgotinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,188 participants
- Where
- 486 sitesin 40 countries
- Study dates
- 17 Mar 2017to 1 Aug 2023
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must have the ability to understand and sign a written informed consent form (ICF), which must be obtained prior to initiation of study procedures associated with this trial
- Must have enrolled in a CD parent protocol, GS-US-419-4015, GS-US-419-4016 or GS-US-419-3895 or any other Gilead/Galapagos sponsored filgotinib treatment study for CD
- Females of childbearing potential must have a negative pregnancy test at Day 1 and must agree to continued monthly pregnancy testing during use of filgotinib treatment
- Female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception for the duration described in the protocol
- Willingness to refrain from live or attenuated vaccines during the study and for 12 weeks after last dose of study drug
- Must have completed all required procedures or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study for CD
Who cannot join
- Known hypersensitivity to the study drug
- Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease, alcohol or drug abuse) that, in the opinion of the Investigator or sponsor, would make the individual unsuitable for the study or would prevent compliance with the study protocol
- Females of reproductive potential who are unwilling to abide by protocol-specified contraceptive methods as defined in the protocol
- Use of prohibited concomitant medications as outlined in the study protocol
- NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Trial locations and contacts
486 sites in 40 countries.
486 sites in 40 countries
United States100 sites
Investigative Clinical Research
Annapolis, Maryland, 21401
Texas Clinical Research Institute
Arlington, Texas, 76012
Illinois Gastroenterology Group - Arlington Heights
Arlington Heights, Illinois, 60005
University of Colorado Denver and Hospital
Aurora, Colorado, 80045
Pinnacle Clinical Research
Austin, Texas, 78757
University of Maryland Medical Center
Baltimore, Maryland, 21201
Inquest Clinical Research
Baytown, Texas, 77521
Massachusetts General Hospital - Crohn's and Colitis Center
Boston, Massachusetts, 02114
HP Clinical Research
Bountiful, Utah, 84010
NY Scientific
Brooklyn, New York, 11235
Charlotte Gastroenterology & Hepatology, PLLC
Charlotte, North Carolina, 28207
University of Virginia Health System
Charlottesville, Virginia, 22908
Charlottesville Medical Research Center, LLC
Charlottesville, Virginia, 22911
WR-ClinSearch, LLC
Chattanooga, Tennessee, 37421
Gastroenterology Associates of Tidewater
Chesapeake, Virginia, 23320
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan, 48047
MGG Group Co., Inc., Chevy Chase Clinical Research
Chevy Chase, Maryland, 20815
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611
The University of Chicago Medical Center (Clinic)
Chicago, Illinois, 60637
Consultants for Clinical Research
Cincinnati, Ohio, 45219
UC Health Physicians Clifton
Cincinnati, Ohio, 45219
Gastro Center of Maryland
Columbia, Maryland, 21045
Advanced Research, LLC
Coral Springs, Florida, 33067
Southern California Research Center, Inc.
Coronado, California, 92118
Digestive Health Specialists Of The Southeast
Dothan, Alabama, 36305
AGA Clinical Research Associates, LLC
Egg Harbor, New Jersey, 08234
Fargo Gastroenterology and Hepatology Clinic
Fargo, North Dakota, 58103
Connecticut GI, PC - Research Division
Farmington, Connecticut, 06032
San Antonio Military Medical Center,
Fort Sam Houston, Texas, 78219
UF Clinical Research Center
Gainesville, Florida, 32610
DHAT Research Institute
Garland, Texas, 75044
Gastro One
Germantown, Tennessee, 38138
Spectrum Health Butterworth Hospital
Grand Rapids, Michigan, 49546
NYU Langone Long Island Clinical Research Associates
Great Neck, New York, 11021
Illinois Gastroenterology Group - Gurnee
Gurnee, Illinois, 60031
Meritus Center for Clinical Research
Hagerstown, Maryland, 21742
Great Lakes Medical Research, LLC
Harrisburg, Pennsylvania, 17110
Kelsey-Seybold Clinic
Houston, Texas, 77025
Baylor College of Medicine - McNair Campus
Houston, Texas, 77030
The Methodist Hospital
Houston, Texas, 77030
The University of Texas Health Science Center at Houston
Houston, Texas, 77030
Centex Studies, Inc.
Houston, Texas, 77058
Gulf Coast Research Group
Houston, Texas, 77098
Indiana University
Indianapolis, Indiana, 46202
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
University of Mississippi Medical Center
Jackson, Mississippi, 39216
University of Kansas Medical Center
Kansas City, Kansas, 66160
Kansas City Research Institute
Kansas City, Missouri, 64131
Florida Research Institute
Lakewood Rch, Florida, 34211
Florida Center for Gastroenterology
Largo, Florida, 33777
Las Vegas Medical Research
Las Vegas, Nevada, 89113
South Denver Gastroenterology, PC
Lone Tree, Colorado, 80124
Cedars Sinai Medical Center
Los Angeles, California, 90048
University of Louisville, Clinical Trials Unit
Louisville, Kentucky, 40202
Gastroenterology Associates Of Central Georgia, LLC
Macon, Georgia, 31201
University of Wisconsin Hospital & Clinics
Madison, Wisconsin, 53705
Gastrointestinal Specialists of Georgia
Marietta, Georgia, 30060
Great Lakes Gastroenterology Research, LLC
Mentor, Ohio, 44060
University of Miami Crohn's and Colitis Center
Miami, Florida, 33136
Advanced Pharma CR, LLC
Miami, Florida, 33147
Cordova Research Institute
Miami, Florida, 33155
Vista Health Research, LLC
Miami, Florida, 33176
Paramount Medical Research & Consulting, LLC
Middleburg Heights, Ohio, 44130
Wisconsin Center for Advanced Research, a division of GI Associates, LLC
Milwaukee, Wisconsin, 53215
Delta Research Partners, LLC
Monroe, Louisiana, 71201
Gastroenterology Group of Naples
Naples, Florida, 34102
Quality Medical Research
Nashville, Tennessee, 37211
Vanderbilt University Medical Center - IBD Clinic
Nashville, Tennessee, 37212
New York University School of Medicine / NYU Gastroenterology Associates
New York, New York, 10016
Lenox Hill Hospital
New York, New York, 10028
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
Gastroenterology Associates of Orangeburg
Orangeburg, South Carolina, 29118
Center for Interventional Endoscopy - Florida Hospital
Orlando, Florida, 32803
Gulf Region Clinical Research Institute
Pensacola, Florida, 32514
Advanced Medical Research Center
Port Orange, Florida, 32127
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York, 12601
Carolina's GI Research LLC
Raleigh, North Carolina, 27607
Inland Empire Clinical Trials, LLC
Rialto, California, 92377
McGuire DVAMC
Richmond, Virginia, 23249
Virginia Commonwealth University
Richmond, Virginia, 23298
Mayo Clinic
Rochester, Minnesota, 55902
Clinical Associates in Research Therapeutics of America, LLC
San Antonio, Texas, 78212
Gastroenterology Research of San Antonio
San Antonio, Texas, 78229
Pinnacle Clinical Research
San Antonio, Texas, 78229
UC San Diego Health Systems
San Diego, California, 92093
Kaiser Permanente
San Francisco, California, 94118
TDDC San Marcos
San Marcos, Texas, 78666
Clearview Medical Research, LLC
Santa Clarita, California, 91351
Louisiana Research Center, LLC
Shreveport, Louisiana, 71105
Texas Digestive Disease Consultants
Southlake, Texas, 76092
Washington University School of Medicine
St Louis, Missouri, 63110
Arizona Digestive Health - Sun City
Sun City, Arizona, 85351
Atlanta Gastroenterology Specialist, PC
Suwanee, Georgia, 30024
Tampa General Hospital
Tampa, Florida, 33606
Spring Gastroenterology
The Woodlands, Texas, 77380
Options Health Research LLC
Tulsa, Oklahoma, 74104
Tyler Research Institute, LLC
Tyler, Texas, 75701
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, 20007
Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center
Wyoming, Michigan, 49519
Florida Medical Clinic, P.A
Zephyrhills, Florida, 33540
Japan40 sites
Ohmori Toshihide gastro-intestinal Clinic
Ageo-shi, 362-0075
Tokyo Medical and Dental University Hospital
Bunkyō City, 113-8519
Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital
Chūōku, 060-0033
Japanese Red Cross Fukuoka Hospital
Fukuoka, 815-8555
Tokai University Hachioji Hospital
Hachiōji, 192-0032
Hiroshima Prefectural Hospital
Hiroshima, 734-8530
Fukuoka University Hospital
Jonan-ku, 814-0180
Saitama Medical Center, Saitama Medical University
Kawagoe, 350-8550
Kitakyushu City Hospital Organization Kitakyushu Municipal Medical Center
Kitakyushu-shi, 802-0077
Yamanashi Prefectural Central Hospital
Kofu, 400-8506
Kurume University Hospital
Kurume-shi, 830-0011
Hidaka Coloproctology Clinic
Kurume-shi, 839-0809
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, 602-8566
The Jikei University Hospital
Minatoku, 105-8471
Kitasato University Kitasato Institute Hospital
Minatoku, 108-8642
Kyorin University Hospital
Mitaka-shi, 181-8611
Iwate Medical University Hospital
Morioka, 020-8505
Aichi Medical University Hospital
Nagakute-shi, 480-1195
Nagasaki University Hospital
Nagasaki, 8528501
Nagoya City University Hospital
Nagoya, 467-8602
Saiseikai Niigata Daini Hospital
Nishiku, 950-1104
Hyogo College of Medicine College Hospital
Nishinomiya, 663-8501
Ishida IBD Clinic
Ōita, 870-0823
Okayama University Hospital
Okayama, 700-8558
Kinshukai Infusion Clinic
Osaka, 530-0011
Osaka City University Hospital
Osaka, 545-8586
Wakakusa-Daiichi Hospital
Osaka, 579-8056
Shiga University of Medical Science Hospital
Ōtsu, 520-2192
Saga-Ken Medical Centre Koseikan
Saga, 840-8571
Saga University Hospital
Saga, 849-8501
Tokito Clinic
Saitama, 336-0963
Toho University Sakura Medical Center
Sakura, 285-8741
Sapporo Higashi Tokushukai Hospital
Sapporo, 065-0033
National Hospital Organization Sendai Medical Center
Sendai, 983-8520
Osaka University Hospital
Suita, 565-0871
Kagawa Prefectural Central Hospital
Takamatsu, 760-8557
National Hospital Organization Takasaki General Medical Center
Takasaki-shi, 3700829
Ieda Hospital
Toyota-shi, 470-1219
Wakayama Medical University Hospital
Wakayama, 641-8509
Yokohama Health Medicine Association Kannai Suzuki Clinic
Yokohama, 231-0012
India33 sites
Kaizen Hospital
Ahmedabad, 380052
Victoria Hospital, Bangalore Medical College and Research Institute (BMCRI)
Bangalore, 560002
M S Ramaiah Medical College and Hospital
Bangalore, 560054
Apollo Speciality Hospital
Chennai, 600035
VGM Hospital Institute of Gastroenterology
Coimbatore, 641005
Lourdes Hospital
Ernākulam, 682012
Fortis Memorial Research Institute
Gūrgaon, 122002
Gleneagles Global Hospital
Hyderabad, 500004
Citizens Specialty Hospital
Hyderabad, 500019
Centre for Liver Research & Diagnostics
Hyderabad, 500058
SR Kalla Memorial Gastro and General Hospital
Jaipur, 302001
S.M.S Hospital
Jaipur, 302004
Lakeshore Hospital and Research Centre Ltd
Kochi, Kerala, 682040
School of Digestive & Liver Diseases
Kolkata, 700020
King George's Medical University
Lucknow, 226003
Dayanand Medical College & Hospital
Ludhiana, 141001
Kasturba Medical College (KMC) Hospital
Mangaluru, 575001
Seth G.S. Medical College & KEM Hospital
Mumbai, 400012
S.L. Raheja Hospital (A Fortis Associate)
Mumbai, 400016
Lokmanya Tilak Municipal General Hospital
Mumbai, 400022
Midas Multispeciality Hospital Pvt. Ltd
Nagpur, 440010
Suretech Hospital & Research Centre Ltd
Nagpur, 440012
All India Institute of Medical Sciences
New Delhi, 110029
Department of Surgery, B.J. Government Medical College & Sassoon General Hospital
Pune, 411001
Grant Medical Foundation Ruby Hall Clinic
Pune, 411001
Universal Hospital
Pune, 411011
Shree Giriraj Multispeciality Hospital
Rajkot, 360002
Gandhi Hospital
Secunderabad, 500003
Institute of Gastroenterology & Liver Disease. Sunshine Hospitals
Secunderabad, 500003
Surat Institute of Digestive Sciences
Surat, 395002
Kasturba Hospital Medical College
Udupi, 576104
Sterling Hospital
Vadodara, 390007
Samvedna Hospital
Varanasi, 221005
Germany25 sites
Charite Universitaetsmedizin Berlin
Berlin, 10117
Medizinisches Versorgungszentrum Delitzsch
Berlin, 10825
Charite - Universitatsmedizin Berlin
Berlin, 13353
DRK Kliniken Berlin - Westend - Klinik fuer Innere Medizin
Berlin, 14050
Stadtisches Klinikum Braunschweig gGmbH
Braunschweig, 38126
Universitaetsklinik Koln
Cologne, 50937
Universitatsklinikum Dresden
Dresden, 01307
Agaplesion Markus Krankenhaus
Frankfurt am Main, 60431
CED Studien UG, Interdisciplinary Crohn Colitis Center (iCCC)
Frankfurt am Main, 60594
Universitatsklinikum Freiburg
Freiburg im Breisgau, 79106
Asklepios Westklinikum Hamburg
Hamburg, 22559
Medizinische Hochschule Hannover
Hanover, 30625
Universitatsklinikum Heidelberg
Heidelberg, 69120
Praxis fur Gastroenterologie
Heidelberg, 69121
Gastroenterologische Gemeinschaftspraxis Herne
Herne, 44623
Universitatsklinikum Jena
Jena, 07747
Universitatsklinikum Schleswig-Holstein
Kiel, 24105
EUGASTRO GmbH
Leipzig, 04103
Universitatsklinikum Leipzig
Leipzig, 04103
Klinikum Luneburg
Lüneburg, 21339
Gastroenterologische Gemeinschaftspraxis Minden
Minden, 32423
Klinikum der Universitat Munchen - Grosshadern
München, 81377
Universitaetsmedizin Rostock, Zentrum fuer Innere Medizin
Rostock, 18057
Universitaetsklinikum Tuebingen
Tübingen, 72074
Universitatsklinikum Ulm, Zentrum Fur Innere Medizin
Ulm, 89081
Poland24 sites
Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Gastroenterologii i Chorob Wewnetrznych
Bialystok, 15-276
VITAMED Galaj i Cichomski spólka jawna
Bydgoszcz, 85-079
Szpital Uniwersytecki nr 2 im. Dr. Jana Biziela w Bydgoszczy, Centrum Endoskopii Zabiegowej, Poradnia Chorob Jelitowych
Bydgoszcz, 85-168
Gabinet Lekarski Janusz Rudzinski
Bydgoszcz, 85-681
NZOZ INTER-MED, Centrum Endoskopowe
Częstochowa, 42-217
Niepubliczny Zaklad Opieki Zdrowotnej ALL-MEDICUS
Katowice, 40-659
Gabinet Endoskopii Przewodu Pokarmowego
Krakow, 31-009
Krakowskie Centrum Medyczne Sp. z o.o
Krakow, 31-501
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Uniwerstyeckiego Szpitala Klinicznego nr 1 im. Norberta Barlickiego
Lodz, 90-153
Trialmed Crs
Piotrkow Trybunalski, 97-300
Clinical Research Center Sp. z o.o. Medic-R Sp.k.
Poznan, 60-848
Gabinet Lekarski Dr. Hab. N. Med. Bartosz Korczowski
Rzeszów, 35-301
Endoskopia Sp. z o.o.
Sopot, 81-756
Twoja Przychodnia-Szczecinskie Centrum Medyczne
Szczecin, 71-434
GASTROMED Kopon, Zmudzkinski i Wspolnicy Sp. j. Specjalistyczne Centrum Gastrologii i Endoskopii
Torun, 87-100
H-T.Centrum Medyczne Spolka z Ograniczona Odpowiedzialnoscia Sp.K.
Tychy, 43-100
Centrum Zdrowia MDM
Warsaw, 00-635
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, 00-728
Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administacji w Warszawie
Warsaw, 02-507
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie
Warsaw, 02-781
Medical Concierge Centrum Medyczne
Warsaw, 02-798
Niepubliczny Zaklad Opieki Zrodotnej VIVAMED Jadwige Miecz
Warsaw, 03-580
Bodyclinic
Warsaw, 03-712
Centrum Medyczne Oporow
Wroclaw, 52-416
France23 sites
CHU Amiens Picardie
Amiens, 80054
CHU de Caen
Caen, 14033
CHU de Clermont-Ferrand - Hopital d'Estaing
Clermont-Ferrand, 63003
APHP - Hopital Beaujon - Clichy - Universite Paris VII
Clichy, 92110
Centre Hospitalier Intercommunal de Creteil
Créteil, 94010
CHU de Dijon Bourgogne - Hopital Francois Mitterand
Dijon, 21079
CHU Grenoble Alpes
La Tronche, 38700
Hopital Universitaire de Bicetre
Le Kremlin-Bicêtre, 94270
Centre Hospitalier Regional Universitaire de Lille
Lille, 59000
Hopital Nord
Marseille, 13015
Hopital Saint Joseph
Marseille, 13285
CHU de Montpellier-Hopital Saint Eloi
Montpellier, 34295
CHU Hotel-Dieu
Nantes, 44093
Hopital de l'Archet 2
Nice, 06202
CHU de Bordeaux - Hopital Haut Leveque
Pessac, 33600
Centre Hospitalier Universitaire de Lyon Sud
Pierre-Bénite, 69495
CH Annecy Genevois - Site d'Annecy
Pringy, 74374
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
Rennes, 35033
CHU de Saint Etienne - Hopital Nord
Saint-Priest-en-Jarez, 42055
Nouvel Hopital Civil
Strasbourg, 67091
Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre
Strasbourg, 67098
CHU de Toulouse - Hopital Rangueil
Toulouse, 31059
CHU de Nancy - Hopital Brabois Adultes
Vandœuvre-lès-Nancy, 54511
Australia16 sites
Emeritus Research
Camberwell, Victoria, 3124
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050
Monash Medical Centre
Clayton, Victoria, 3168
St. Vincent's Hospital Sydney
Darlinghurst, New South Wales, 2010
Footscray Hospital
Footscray, Victoria, 3011
Austin Health
Heidelberg, Victoria, 3084
Nepean Hospital
Kingswood, New South Wales, 2747
Cabrini Hospital
Malvern, Victoria, 3144
Alfred Hospital
Melbourne, Victoria, 3004
Coastal Digestive Health
Mountain Creek, Queensland, 4557
Coral Sea Clinical Research Institute (Mackay)
North Mackay, Queensland, 4740
Royal Melbourne Hospital
Parkville, Victoria, 3050
Mater Misericordiae Ltd
South Brisbane, Queensland, 4101
Wollongong Hospital
Wollongong, New South Wales, 2500
The Queen Elizabeth Hospital
Woodville South, South Australia, 5011
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102
Ukraine16 sites
Multispecialty Clinical Hospital of Intensive Treatments and Emergency Medical Care
Chernivtsi, 58000
Regional Municipal Institution "Chernivtsi Regional Clinical Hospital", Surgical Department
Chernivtsi, 58000
State Institution "Institute of Gastroenterology of National Academy of Medical Sciences of Ukraine"
Dnipropetrovsk, 49000
Ivanto-Frankivsk Central City Clinic Hospital, Therapy Department #1. State Higher Education Institution Ivano-Frankivsk National
Ivano-Frankivsk, 76018
Municipal Health Care Institution "Kharkiv City Clinical Hospital #2 named after prof. O. O. Shalimov", Proctology Department
Kharkiv, 61037
Municipal Institution of Health Care "Regional Hospital of War Veterans", Therapeutic Department No1
Kharkiv, 63101
Treatment and Diagnostic Center of Private Enterprise of Private Production Company "Acinus"
Kropyvnytskyi, 25006
Kyiv City Clinical Hospital No. 18, Proctology Department
Kyiv, 01030
Municipal Non-profit Enterprise "Consultative and Diagnostic Center" of Pechersk District of Kyiv, Therapy Department
Kyiv, 1103
Municipal Institution "Odesa Regional Clinical Hospital", Regional Gastroenterology Center based on Surgery Department
Odesa, 65025
Ternopil Regional Clinical Hospital, Regional Center of Gastroenterology with Hepatology
Ternopil, 46002
Municipal Institution "Uzhgorod District Hospital", Therapy Department
Uzhhorod, 88009
Vinnytsia Regional Clinical Hospital of War Veterans, Therapy Department #1
Vinnytsia, 21005
M.I. Pyrogov Vinnytsia Regional Clinical Hospital, Gastroenterology Department
Vinnytsia, 21018
Medical Center LLC "Health Clinic"
Vinnytsia, 21029
Municipal Institution "Zaporizhzhya Regional Clinical Hospital" of Zaporizhzhya Regional Council
Zaporizhzhya, 69600
Italy14 sites
UOC Gastroenterologia II
Castellana Grotte, 70013
U.O. Fisiopatologia Digestiva
Catanzaro, 88100
UOC Medicina Interna
Cento, 44042
Ospedale Clinicizzato SS. Annunziata - Dipartimento di Medicina
Chieti, 66100
Gastroenterologia clinica - Azienda Ospedaliero-Universitaria Careggi
Florence, 50134
Endocsopia Digestiva Centralizzata
Milan, 20121
UO Gastroenterologia
Modena, 40124
UOC Gastroenterologia
Padova, 35128
Azienda Ospedaliero-Universitaria Pisana - Presidio Ospedaliero Cisanello
Pisa, 56124
UOC Gastroenterologia ed Endoscopia Digestiva
Roma, 00128
UOC di Gastroenterologia ed Endoscopia Digestiva
Roma, 00133
UOC Medicina Interna a Gastroenterologia
Roma, 00168
Istituto Clinico Humanitas
Rozzano, 20089
A.S.O. Ordine Mauriziano Di Torino S.C.
Torino, 10122
United Kingdom14 sites
Queen Elizabeth Hospital
Birmingham, B15 2WB
The Pennine Acute Hospitals NHS Trust
Bury, BL9 7TD
Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB20QQ
NHS Lothian
Edinburgh, EH4 2XU
Royal Devon and Exeter NHS Foundation Trust
Exeter, EX2 5DW
Glasgow Clinical Research Facility - Queen Elizabeth University Hospital
Glasgow, G51 4TF
NHS Greater Glasgow and Clyde
Glasgow, G52 3NQ
Wycombe Hospital
High Wycombe, HP11 2TT
St George's University Hospitals NHS Foundation Trust
London, SW17 0QT
Imperial College Healthcare NHS Trust, St Mary's Hospital
London, W2 1NY
Norfolk and Norwich University Hospital NHS Foundation Trust
Norwich, Norfolk, NR4 7UY
Oxford University Hospitals NHS Trust
Oxford, OX3 9DU
St Helens and Knowsley Teaching Hospitals NHS Trust
Prescot, L35 5DR
Southampton National Institute for Health Research, Wellcome Trust Clinical Research Facility
Southampton, SO16 6YD
Spain13 sites
Hospital Universitari Germans Trias i Pujol
Badalona, 08916
Centro Medico Teknon
Barcelona, 08022
Hospital del Mar
Barcelona, 8003
Complejo Hospitalario Universitario de Ferrol
Ferrol, 15405
Hospital Universitario de Gran Canaria "Dr. Negrin"
Las Palmas de Gran Canaria, 35010
Hospital General Universitario Gregorio Maranon
Madrid, 28007
Hospital Clinico San Carlos
Madrid, 28040
Hospital Universitario de Fuenlabrada
Madrid, 28942
Hospital Universitario Central de Asturias
Oviedo, 33006
Hospital de Montecelo
Pontevedra, 36071
Hospital de Sagunto
Sagunto, 46520
Hospital Universitario Virgen del Rocío
Seville, 41013
Hospital de Galdakao-Usandolo
Usansolo, 48960
South Korea12 sites
Pusan National University Hospital
Busan, 49241
Yeungnam University Hospital
Daegu, 42415
Kyung Hee University Hospital
Guri-si, 471-701
Hanyang University Guri Hospital
Gyeonggi-do, 11923
CHA Bundang Medical Center, CHA University
Seongnam-si, 463-712
Seoul National University Hospital
Seoul, 03080
Kangbuk Samsung Hospital
Seoul, 03181
Yonsei University Health System, Severance Hospital
Seoul, 03722
Asan Medical Center
Seoul, 05505
Division of Gastroenterology, Department of Medicine, Samsung Medical Center
Seoul, 06351
The Catholic University of Korea, St. Vincent's Hospital
Suwon, 16247
Yonsei University Wonju Severance Christian Hospital
Wŏnju, 220-701
Canada11 sites
Barrie GI Associates
Barrie, L4M 7G1
University of Calgary, Heritage Medical Research Clinic
Calgary, T2N 4Z6
Hamilton Health Sciences Corporation, McMaster University Medical Centre
Hamilton, L8S 4K1
London Health Sciences Centre - University Hospital
London, N6A 5A5
TIDHI Innovation, Inc.
North York, M6A 3B4
ABP Research Services
Oakville, L6L 5L7
Royal University Hospital
Saskatoon, S7N 0W8
Mount Sinai Hospital
Toronto, M5T 3L9
The Gordon and Leslie Diamond Health Care Centre
Vancouver, V5Z 1M9
Toronto Digestive Disease Associates Inc.
Vaughan, L4L 4Y7
Percuro Clinical Research Ltd.
Victoria, V8V 3P9
Israel11 sites
Emek Medical Center
Afula, 18101
Soroka Medical Center
Beersheba, 8410101
Bnai Zion Medical Center
Haifa, 31048
Rambam Medical Health Care Campus
Haifa, 3109601
The Edith Wolfson Medical Center
Holon, 5822012
Shaare Zedek Medical Center
Jerusalem, 9103102
Hadassah Medical Center
Jerusalem, 9112001
Meir MC
Kefar Sava, 4428164
Rabin Medical Center
Petah Tikva, 4941492
The Chaim Sheba Medical Center
Ramat Gan, 5265601
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239
Romania11 sites
MedLife, Gastroenterologie
Bucharest, 010719
Spitalul Universitar de Urgenta Militar Central Dr. Carol Davila - Sectia Clinica de Gastroenterologie
Bucharest, 010825
S.C. Centrul Medical Sana S.R.L., Gastroenterologie
Bucharest, 011025
Delta Health Care/ Ponderas Academic Hospital
Bucharest, 014142
Spitalul Clinic Colentina - Sectia de Spitulal Clinic Colentina, Gastroenterologie
Bucharest, 020125
MedLife, Gastroenterologie
Bucharest, 031784
Spitalul Universitar de Urgenta Bucuresti - Sectia Medicina Interna II
Bucharest, 050098
Gastromedica SRL, Gastroenterologie
Iași, 700506
Cabinet Particular Policlinic Algomed SRL
Timișoara, 300002
Centrul Medical Tuculanu, Gastroenterologie
Timișoara, 300168
S.C. Policlinica Dr. Citu S.R.L.- Gastroenterologie
Timișoara, 300594
Taiwan11 sites
Changhua Christian Hospital
Changhua, 500
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807
Far Eastern Memorial Hospital
New Taipei City, 220
Chang Shan Medical University Hospital
Taichung, 40201
China Medical University Hospital
Taichung, 40447
National Cheng Kung University Hospital
Tainan, 7428
National Taiwan University Hospital
Taipei, 100
Mackay Memorial Hospital, Taipei
Taipei, 104
Taipei Veterans General Hospital
Taipei, 112
Tri-Service General Hospital
Taipei, 114
Chang Gung Medical Foundation, Chang Gung Memorial Hospital, Linkou Branch
Taoyuan, 33305
Russia10 sites
State Budgetary Healthcare Institution "Chelyabinski Regional Clinical Hospital"
Chelyabinsk, 454076
State Budgetary Institution of Health Irkustsk Order "Badge of Honor" Regional Clinical Hospital
Irkutsk, 669079
State Budgetary Healthcare Institution of Moscow Region "Moscow Regional Clinical Research Institute n.a. M.F. Vladimirskiy"
Moscow, 129110
State Budgetary Healthcare Institution of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. N.A.
Nizhny Novgorod, 603126
State Budgetary Healthcare Institution of the Novosibirsk Region "State Novosibirsk Regional Clinical Hospital"
Novosibirsk, 630087
State Budgetary Institution of Health of Novosibirsk Region "City Clinical Hospital #12"
Novosibirsk, 630091
Saint Petersburg State Budgetary Healthcare Institution "City Polyclinic #38"
Saint Petersburg, 191015
"Scientific Research Centre ECO-safety" LLC
Saint Petersburg, 196143
"PolyClinic EXPERT" LLC
Saint Petersburg, 197110
State Healthcare Institution "Regional Clinical Hospital"
Saratov, 410053
Belgium9 sites
GZA Ziekenhuizen, campus Sint-Vincentius
Antwerp, 2018
Imelda General Hospital
Bonheiden, 2820
CUB Hopital Erasme
Brussels, 1070
Universitair Ziekenhuis Antwerpen
Edegem, 2650
Universitair Ziekenhuis Gent
Ghent, 9000
Universitair Ziekenhuis Leuven
Leuven, 3000
Centre Hospitalier Chretien (CHC) - Clinique Saint-Joseph
Liège, 4000
CHR Citadelle
Liège, 4000
AZ Delta
Roeselare, 8800
Netherlands9 sites
NZW Alkmaar (Noordwest Ziekenhuisgroep)
Alkmaar, 1815 JD
VU Medisch Centrum
Amsterdam, 1081 HV
Academic Medical Center (AMC)
Amsterdam, 1105 AZ
Gelre Hospital
Apeldoorn, 7334
Universitair Medisch Centrum Groningen
Groningen, 9700 RB
Maastricht University Medical Centre
Maastricht, 6229 HX
Erasmus University Medical Center
Rotterdam, 3015 CE
Elisabeth-TweeSteden Hospital
Tilburg, 5022
University Medical Center Utrecht
Utrecht, 3584 CX
Hungary8 sites
Bekes Megyei Kosponti Korhaz, Dr. Rethy Pal Tagkorhaz, IV. Belgyogyaszat - 2. Gasztroenterologia
Békéscsaba, 5600
Szent Margit Korhaz, Gasztroenterológiai Osztály
Budapest, 1032
Clinexpert Egeszsegugyi Szolgaltato es Kereskedelmi Kft.
Budapest, 1033
Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet, Kozponti Felnott Szakrendelo
Budapest, 1097
Szent Janos Korhaz es Eszak-budai Egitett Korhazak, I. Belgyogyaszati - Gasztroenterologiai Osztaly
Budapest, 1125
Debreceni Egyetem Klinikai Kozpont, II. sz. Belgyogyaszati Klinika, Gasztroenterologia
Debrecen, 4032
Bugat Pal Korhaz, Belgyogyaszat
Gyöngyös, 3200
Karolina Korhaz es Rendelointezet, Altalanos Belgyogyaszat-Gasztroenterologia
Mosonmagyaróvár, 9200
Portugal8 sites
Hospital de Braga
Braga, 4710-243
Centro Hospitalar e Universitario de Coimbra, E.P.E.
Coimbra, 3000-075
Centro Hospitalar Cova de Beira, EPE
Covilha, 6200-251
Centro Hospitalar do Algarve EPE
Faro, 8000-386
Hospital da Senhora da Oliveira Guimaraes, E.P.E.
Guimarães, 4835-044
Hospital Beatriz Angelo
Loures, 2674-514
Centro Hospitalar de Sao Joao, EPE
Porto, 4200-319
Unidade Local de Saúde do Alto Minho
Viana do Castelo, 4904-858
New Zealand7 sites
Christchurch Hospital
Christchurch, 8011
Southern District Health Board - Dunedin Hospital
Dunedin, 9016
Auckland City Hospital
Grafton, 1023
Waikato Hospital
Hamilton, 3240
Wellington Hospital
Newtown, 6021
Bay of Plenty District Health Board - Tauranga Hospital
Tauranga, 3112
Hutt Valley District Health Board - Hutt Valley Hospital
Wellington, 5010
Czechia5 sites
Hepato-Gastroenterology HK, s.r.o.
Hradec Králové, 500 12
Oblastni nemocnice Mlada Boleslav, a.s., nemocnice Stredoceskeho kraje, Gastroenterologicke oddeleni
Mladá Boleslav, 293 01
G.E.P. Clinic, s r.o.
Prague, 130 00
Thomayerova nemocnice, Interni klinika 3. LF UK a TN
Prague, 140 00
ISCARE a.s. (Klinicke centrum ISCARE), Klinicke a vyzkumne centrum pro strevni zancty
Prague, 190 00
Greece5 sites
Hippokration Hospital of Athens
Athens, 11527
University General Hospital "Attikon", 2nd Propaedeutic Internal Medicine Dept. and Research Unit, Hepatogastroenterology Unit
Athens, 12462
University General Hospital of Ioannina, Gastroenterology Department, Internal Medicine Division
Ioannina, 45332
University General Hospital of Patras "Panagia I Voithia", Gastroenterology Department, Internal Medicine Division
Pátrai, 26504
Hippokratio General Hospital of Thessaloniki "Hippokratio" 4th Internal Medicine Department of Aristotle University of Thessaloniki
Thessaloniki, 54642
Malaysia5 sites
Universiti Kebangsaan Malaysia Medical Center
Cheras, 56000
Hospital Pulau Pinang
George Town, 10990
Hospital Queen Elizabeth
Kota Kinabalu, 88586
University Malaya Medical Centre
Kuala Lumpur, 59100
Hospital Tengku Ampuan Afzan
Kuantan, 25100
Serbia5 sites
Clinical Hospital Center Zemun
Belgrade, 11000
University Hospital Medical Center Bezanijska kosa
Belgrade, 3010-777
Clinical Center of Serbia
Belgrade, 3618-445
Zvezdara University Medical Center
Belgrade, 3810-970
Clinical Center of Vojvodina
Novi Sad, 21000
Bulgaria4 sites
Medical Center - Complete Medical Solutions OOD
Samokov, 2000
Medical Center - "Tsaritsa Yoanna" EOOD
Sliven, 8800
"MDHAT Dr. St.Cherkezov" AD
Veliko Tarnovo, 5000
MHAT "Sveta Petka" AD
Vidin, 3700
Hong Kong4 sites
Princess Margaret Hospital
Hong Kong
Queen Mary Hospital
Hong Kong
Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital
Shatin
Tuen Mun Hospital
Tuenmen
Ireland4 sites
St. Vincent's University Hospital
Dublin, 4
Beaumont Hospital
Dublin, 9
Wellcome Trust HRB Clinical Research Facility
Dublin, DUBLIN 8
University Hospital Galway
Galway, H91 YR71
Singapore4 sites
National University Hospital
Singapore, 119074
Singapore General Hospital
Singapore, 169608
Tan Tock Seng Hospital
Singapore, 308433
Changi General Hospital
Singapore, 529889
Sri Lanka4 sites
National Hospital of Sri Lanka
Colombo, 00700
Karapitiya Teaching Hospital
Galle, 80000
Kandy Teaching Hospital
Kandy, 20000
Colombo North Teaching Hospital
Ragama, 11010
Austria3 sites
Universitatsklinik Innsbruck
Innsbruck, 6020
Klinikum Klagenfurt am Wörthersee, Abt. Für Inn. Med. & Gastroenterol, (IMuG), Hepatol., Endokrinol., Rheumatol., & Nephrol.
Klagenfurt, 9020
AKH-Medizinische Universitat Wien
Vienna, 1090
Croatia3 sites
University Hospital Center Osijek
Osijek, 31 000
Clinical Hospital Dubrava
Zagreb, 10000
University Hospital Center Zagreb
Zagreb, 10000
Georgia3 sites
Unimed Ajara LLC - Batumi Referral Hospital
Batumi, 6010
Medi Club Georgia LLC
Tbilisi, 0160
Ltd. Unimed Kakheti - Telavi Referral Hospital
Telavi, 2200
Slovakia3 sites
Cliniq s. r. o., Gastroenterologicke centrum Ruzinov
Bratislava, 82007
KM Management, s.r.o., Gastroenterologicke a hepatologicke centrum Nitra
Nitra, 950 01
Gastro I., s.r.o.
Prešov, 8001
South Africa3 sites
Dr MJ Prins
Cape Town, 7500
Dr John P Wright
Cape Town, 7708
Peermed Clinical Trial Centre
Johannesburg, 1619
Sweden2 sites
Danderyds Sjukhus AB
Danderyd, SE-18288
Akademiska Sjukhuset
Uppsala, 75185
Switzerland2 sites
Intesto Gastroenterologische Praxis & Crohn-Colitis-Zentrum Bern
Bern, 3012
Universitätsspital Zürich
Zurich, 8091
About this study
Official title: A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Crohn's Disease
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
- Conditions
- Crohn's Disease
- Being tested
- Filgotinib, Placebo
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FilgotinibDrug
Also called GS-6034, GLPG0634, Jyseleca®
Tablet administered orally once a day
PlaceboDrug
Tablet administered orally once a day
| Study group | Role | What they receive |
|---|---|---|
| Filgotinib 200 mg | Experimental | Participants who received filgotinib 200 milligrams (mg) blinded and completed the parent study, continued to receive filgotinib 200 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 200 mg.
Participants who exited the parent study due to disease worsening or failure to meet response or remission criteria, with the exception of US and Korean males who were not considered dual-biologic refractory, received filgotinib 200 mg open-label in this study.
Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks). Receives: Drug: Filgotinib |
| Filgotinib 100 mg | Experimental | Participants who received filgotinib 100 mg blinded and completed the parent study, continued to receive filgotinib 100 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 100 mg.
Male participants from the US \& Korea who were not considered dual biologic refractory, and who exited the parent study due to disease worsening or failure to meet response or remission criteria, received filgotinib 100 mg open-label in this study.
Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks). Receives: Drug: Filgotinib |
| Placebo | Placebo comparator | Participants who received placebo and completed the parent study, continued to receive placebo in this extension study. After unblinding of the parent study, participants on placebo treatment discontinued study drug and study participation.
Treatment was administered orally once a day until unblinding of the parent study (up to 308 weeks). Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a participant administered a study drug, and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug whether or not considered related to the study drug. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following:
- Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug
- Any AEs leading to premature discontinuation of study drug.
Measured: From the First Dose to Week 312
Secondary outcomes (3)
Change From Baseline in Patient Reported Outcomes 2 (PRO2) Scores for Liquid or Very Soft Stools
The PRO2 was a composite score based on 2 components of CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain) assessed for 7 days. The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4, higher values mean worse well-being), and number of liquid or very soft stools were summed over the 7 days prior to each visit. The remaining predictors were also weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Change from baseline for number of liquid or very soft stool per day was reported.
Measured: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Change From Baseline in Patient Reported Outcomes (PRO2) Scores for Abdominal Pain
The PRO2 was a composite score based on 2 components of CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain) assessed for 7 days. The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4, higher values mean worse well-being), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Change from baseline in abdominal pain was reported.
Measured: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Change From Baseline in CDAI Scores
The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain), general well-being (0-4, higher values mean worse well-being), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.
Measured: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2016 (estimated)
- Study start17 Mar 2017
- Primary completion1 Aug 2023
- Study completion1 Aug 2023
Why it stopped: development program for filgotinib for participants with Crohn's disease has been stopped
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Crohn's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 1,188 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lakefront Biotherapeutics NV
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Gilead Sciences
- Responsible party
- Sponsor
- Investigators
- Galapagos Study Director, Study director, Lakefront Biotherapeutics NV
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02914600
- Sponsor's protocol ID
- GS-US-419-3896
- Other IDs
- 2016-002763-34, 2016
- Acronym
- DIVERSITY LTE
- Status last verified
- May 2024
- First submitted
- 22 Sep 2016
- Last updated
- 10 Jul 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Crohn's Disease
- ClinicalTrials.gov ID
- NCT02914600
- Acronym / sponsor ID
- DIVERSITY LTE / GS-US-419-3896
- Conditions
- Crohn's Disease
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: development program for filgotinib for participants with Crohn's disease has been stopped
- Enrolment
- 1,188 participants (actual)
- Lead sponsor
- Lakefront Biotherapeutics NVIndustry (pharma, biotech, devices)
- Collaborators
- Gilead Sciences
- Study start
- 17 Mar 2017 (actual)
- Primary completion
- 1 Aug 2023 (actual)
- Study completion
- 1 Aug 2023 (actual)
- First posted
- 26 Sep 2016 (estimated)
- Results
- Posted 10 Jul 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Filgotinib 200 mg | Experimental | Drug: FilgotinibParticipants who received filgotinib 200 milligrams (mg) blinded and completed the parent study, continued to receive filgotinib 200 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 200 mg. Participants who exited the parent study due to disease worsening or failure to meet response or remission criteria, with the exception of US and Korean males who were not considered dual-biologic refractory, received filgotinib 200 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks). |
| Filgotinib 100 mg | Experimental | Drug: FilgotinibParticipants who received filgotinib 100 mg blinded and completed the parent study, continued to receive filgotinib 100 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 100 mg. Male participants from the US \& Korea who were not considered dual biologic refractory, and who exited the parent study due to disease worsening or failure to meet response or remission criteria, received filgotinib 100 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks). |
| Placebo | Placebo comparator | Drug: PlaceboParticipants who received placebo and completed the parent study, continued to receive placebo in this extension study. After unblinding of the parent study, participants on placebo treatment discontinued study drug and study participation. Treatment was administered orally once a day until unblinding of the parent study (up to 308 weeks). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Must have the ability to understand and sign a written informed consent form (ICF), which must be obtained prior to initiation of study procedures associated with this trial
- Must have enrolled in a CD parent protocol, GS-US-419-4015, GS-US-419-4016 or GS-US-419-3895 or any other Gilead/Galapagos sponsored filgotinib treatment study for CD
- Females of childbearing potential must have a negative pregnancy test at Day 1 and must agree to continued monthly pregnancy testing during use of filgotinib treatment
- Female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception for the duration described in the protocol
- Willingness to refrain from live or attenuated vaccines during the study and for 12 weeks after last dose of study drug
Key exclusion criteria (5 listed)
- Known hypersensitivity to the study drug
- Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease, alcohol or drug abuse) that, in the opinion of the Investigator or sponsor, would make the individual unsuitable for the study or would prevent compliance with the study protocol
- Females of reproductive potential who are unwilling to abide by protocol-specified contraceptive methods as defined in the protocol
- Use of prohibited concomitant medications as outlined in the study protocol
- NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FilgotinibAlso: GS-6034, GLPG0634, Jyseleca®Tablet administered orally once a day | Drug | Filgotinib 100 mg, Filgotinib 200 mg |
| PlaceboTablet administered orally once a day | Drug | Placebo |
Primary outcome
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: From the First Dose to Week 312
An AE was defined as any untoward medical occurrence in a participant administered a study drug, and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug whether or not considered related to the study drug. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug.
3 secondary outcomes
Change From Baseline in Patient Reported Outcomes 2 (PRO2) Scores for Liquid or Very Soft Stools
Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Change From Baseline in Patient Reported Outcomes (PRO2) Scores for Abdominal Pain
Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Change From Baseline in CDAI Scores
Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Crohn's Disease
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Galapagos Study Director study director
Lakefront Biotherapeutics NV
486 sites in 40 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Filgotinib in people with Crohn's Disease, run by Lakefront Biotherapeutics NV at 486 sites in 40 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 10 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 486 sites in United States, Japan, India, Germany, Poland and 35 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Jul 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Treatment Emergent Adverse Events (TEAEs) (time frame: From the First Dose to Week 312). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2024.